Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies

In this study, the investigators will collect tissue from patients undergoing trabeculectomy for primary open-angle glaucoma treatment. This tissue would normally be discarded. These trabecular meshwork (TM) cells can be cultured and used experimentally to better understand the mechanisms of glaucoma. These TM biopsies will be cultured on the same day as the trabeculectomy using established techniques.

Study Overview

• Status: Completed
• Conditions: Glaucoma

• Study Type: Observational
• Enrollment (Actual): 12

Contacts and Locations

Study Locations

• United States
  • Florida
    • Tampa, Florida, United States, 33606
      • Tampa General Hosipital
    • Tampa, Florida, United States, 33613
      • Byrd Alzheimer's Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients having glaucoma and undergoing a trabeculotomy

Description

Inclusion Criteria:

• Patients having glaucoma and undergoing a trabeculotomy
• Sign ICF (Informed Consent Form)

Exclusion Criteria:

• None

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy of new glaucoma medications to reduce TM cellular pathologies associated with the disease glaucoma.	TM cell biopsy samples from patients with glaucoma will be harvested and cultured in a laboratory setting to grow primary human TM cells. These cells will be used to test different medications, looking at the medications ability to reduce cellular pathologies commonly seen in TM tissue of patients with glaucoma. Pathologies include myocilin aggregation, and cell death. This will help researchers to determine the most effective compounds in treating glaucoma.	6 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cultured TM cell toxicity caused by new glaucoma medications	Cultured primary TM cells treated with various new medications synthesized to treat cellular pathologies associated with glaucoma, will also be analyzed to look at toxicity caused by the treatments themselves. THis will help to determine the safety of these new medications prior to being administered to patients.	6 weeks

Collaborators and Investigators

• Sponsor: University of South Florida
• Investigators: Principal Investigator: Chad A Dickey, PhD, University of South Florida department of Molecular Medicine and Byrd Alzheimer's Institute; Study Director: Carla Bourne, MD, University of South Florida and Tampa General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2014
• Primary Completion (Actual): July 1, 2015
• Study Completion (Actual): November 1, 2016

Study Registration Dates

• First Submitted: May 21, 2014
• First Submitted That Met QC Criteria: May 27, 2014
• First Posted (Estimated): May 30, 2014

Study Record Updates

• Last Update Posted (Actual): June 26, 2024
• Last Update Submitted That Met QC Criteria: June 24, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Ocular Hypertension; Glaucoma; Glaucoma, Open-Angle
• Other Study ID Numbers: 15309